Research Articles
Preliminary evaluation of furosemide–probenecid interaction in humans

https://doi.org/10.1002/jps.2600690526Get rights and content

Abstract

The pharmacokinetics and pharmacodynamics of intravenous furosemide, 40 mg, were studied in four healthy male subjects in a crossover fashion with and without probenecid pretreatment. In each study, 16 plasma and 10 urine samples were collected over 24 hr. Fluid and electrolyte urinary losses were replaced orally throughout the study. Unchanged furosemide and probenecid were measured using high-pressure liquid chromatography; urinary sodium was measured by flame photometry. Although probenecid caused marked changes in the pharmacokinetic parameters of furosemide (increased area under the curve, decreased plasma and renal clearance, increased half-life, and decreased fraction excreted unchanged in the urine), there was no significant difference in its gross 8-hr natriuretic and diuretic effect. However, analysis of the time course of natriuresis showed a pattern similar to that of the urinary furosemide excretion rate, whereas the plasma concentration was poorly correlated over the entire dose-response curve.

References (33)

  • KirkendallW.M. et al.

    Am. J. Cardiol.

    (1968)
  • KimK.E. et al.

    Am. J. Cardiol.

    (1971)
  • BurgM.B.

    Kidney Int.

    (1976)
  • SeelyJ.F. et al.

    Kidney Int.

    (1977)
  • LinE.T. et al.

    J. Chromatogr.

    (1979)
  • BenetL.Z. et al.

    J. Pharm. Sci.

    (1979)
  • PatakR.V. et al.

    Prostaglandins

    (1975)
  • LeeJ.B. et al.

    Am. J. Med.

    (1976)
  • ZinsG.R.

    Am. J. Med.

    (1975)
  • BitoL.Z.

    Prostaglandins

    (1975)
  • BitoL.Z.

    Prostaglandins

    (1976)
  • StasonW.B. et al.

    Circulation

    (1966)
  • JacobsonH.R. et al.

    Ann. Rev. Pharmacol. Toxicol.

    (1976)
  • BurgM. et al.

    Am. J. Physiol.

    (1973)
  • AndreasenF. et al.

    Eur. J. Clin. Pharmacol.

    (1978)
  • RaneA. et al.

    Clin. Pharmacol. Ther.

    (1978)
  • Cited by (42)

    • Renal drug transporters and their significance in drug-drug interactions

      2016, Acta Pharmaceutica Sinica B
      Citation Excerpt :

      In the following section, we highlight the importance of renal OC and OA drug transporters in mediating clinically significant DDIs. The relevant consequences on pharmacokinetics, pharmacodynamics, and drug-induced nephrotoxicity are illustrated using several well-studied clinical DDI examples as summarized in Table 114,76,81–90. hOCT2 and hMATE1/2-K form a major pathway for renal elimination of small hydrophilic drugs carrying a positive charge.

    • Probenecid: Novel use as a non-injurious positive inotrope acting via cardiac TRPV2 stimulation

      2012, Journal of Molecular and Cellular Cardiology
      Citation Excerpt :

      The authors attributed the observed diuresis only to the renal aspect of probenecid and not to a potential cardiac effect. We scoured the literature, including the original FDA submissions for probenecid approval and found no other references or comments reporting an increase in diuresis specifically relating to probenecid (though several did report on its interactions with other diuretics) [58]. The occasional studies that refer to cardiac issues and probenecid are limited to its use in inflammation and infection but not direct effects on cardiac function [12].

    View all citing articles on Scopus

    Supported in part by National Institutes of Health Grant AM 20884

    D. E. Smith was supported as a National Institutes of Health Pre-doctoral Scholar on Training Grant GM 07175.

    View full text